Systemic lupus erythematosus in the younger patient: survival studies.
One hundred eighty-two patients fulfilling the American Rheumatism Association criteria for the classification of systemic lupus erythematosus (SLE) were followed prospectively. Sixty-seven had the onset of SLE before age 21, 32 before age 16, and 35 between age 16 and 20. All patients received similar therapy. Only 4 patients received cytotoxic agents. Malar blush, cellular casts, and profuse proteinuria were significantly more common in the 0-15 compared to the adult group (age 21 or older). Five-year survival was 100% for children with membranous or focal lupus nephritis and 85% for diffuse proliferative lupus nephritis.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D005921:Glomerulonephritis / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000401:mortality*; D008875:Middle Aged; D011379:Prognosis; D013997:Time Factors
D007166:Immunosuppressive Agents